Luciferase Reporter Cell Line - NIT-1

NIT-1 is a murine pancreatic β-cell line widely used as an in vitro model to study β-cell biology, the function of insulin-secreting cells, and mechanisms underlying autoimmune diabetes. Derived from the non-obese diabetic (NOD) mouse model, the parental NIT-1 cell line retains key characteristics of pancreatic β-cells, including endocrine cell morphology and responsiveness to experimental stimuli relevant to islet cell research. Given its β-cell origin and disease-relevant background, NIT-1 is frequently employed in studies involving β-cell stress, immune-mediated cytotoxicity, cytokine responses, glucose metabolism, and apoptosis, as well as in the evaluation of compounds with the potential to protect or modulate pancreatic β-cell activity. The NIT-1 luciferase reporter cell line is an engineered derivative of the NIT-1 cell line, modified to stably express a luciferase reporter gene.

The NIT-1 luciferase reporter cell line has broad applications in research areas such as diabetes, pancreatic β-cell function, immunology, pharmacology, and cell-based screening. In drug discovery and compound evaluation, this cell line is highly suitable for screening candidate molecules that affect β-cell viability, proliferation, or apoptosis, or that offer protection against toxic stimuli. Since luminescence intensity often correlates with the number of viable cells under appropriately validated conditions, researchers can use the reporter signal to assess cytotoxicity, growth inhibition, or β-cell rescue effects following treatment with cytokines, small molecules, biologics, natural products, metabolic stressors, or immune-related factors. This cell line can also be used to investigate the mechanisms of autoimmune diabetes, including the interactions between β-cells and inflammatory mediators.